NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on TALEN®-edited smart CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, M.A. and virtually on November 8-12, 2022.
Cellectis will present a poster on TALEN®-edited smart CAR T-cells targeting MUC1- expressing solid tumors. MUC1 is a tumor-associated antigen that is overexpressed in triple-negative breast cancer (TNBC) and other solid tumor malignancies.
Title: Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth Poster Number: 217 Presenter: Piril, Erler Ph.D., Scientist II, Immuno-Oncology, Cellectis Date/Time: Thursday, November 10th, posters will be on display from 9:00 AM- 9:00 PM, Hall C
Cellectis will present a poster on innovative T-cell engineering strategies designed to increase the activity of CAR T-cells for solid tumors while mitigating toxicity risk.
Title: TALEN®-edited smart CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy Poster Number: 325 Presenter: Shipra Das Ph.D., Senior Scientist & Team Leader Immuno-Oncology, Cellectis Date/Time: Thursday, November 10th, posters will be on display from 9:00 AM- 9:00 PM, Hall C
Full text of the abstracts will be released on the SITC website at 8:00 a.m. EST on November 7, 2022.
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
For more information, visit www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
For further information, please contact:
Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300
Investor Relation contact: Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Forward-looking Statements This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend,” “expect,” “plan,” “scheduled,” “could,” “may” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of our product candidates. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Spirit has scheduled the Special Meeting of Stockholders to approve the proposed merger with JetBlue later this month.
(Bloomberg) -- India’s expected surge of rich consumers is driving the jewelry unit of Indian conglomerate Tata Group to triple its Zoya-branded luxury stores by 2027.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketThis Is What 7% Mortgages Will Do to the Housing MarketScreening Procedure Fails to Prevent Colon Cancer Deaths in Large StudyCathie Wood Warns of ‘Serious Losses’ in Automobile DebtIt’s Official: The Fed’s in the Red“There is a lot of latent demand fo
It may not be practical — at least for now.
After the annus horribilis of 2022, with the final quarter now in play, investors will be hoping a late-year rally will materialize. According to Carson Group's chief market strategist Ryan Detrick, that’s not such a far-fetched idea. "While October has a reputation for crashes, it is really a bear market killer,” Detrick recently wrote. “Of the past 17 bear (or near bear markets), stocks bottomed in October six times. Could it happen again? With sentiment this pessimistic and extremely positive
The French label's chief brand officer since 2021, Spindler joined the company and its executive committee in 2019.
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. National Fuel (NFG), Herc Holdings (HRI), ONEOK (OKE) and CECO Environmental (CECE) are strong enough to meet financial obligations.
Stocks in Taiwan were down 4% early in the first trading session after the U.S. imposed new limits on exports of semiconductors and chip-making equipment to China.
(Bloomberg) -- US stocks fell for a fourth day as prospects for policy tightening and geopolitical risks weighed on investor sentiment. A gauge of dollar strength rose to the highest level this month.The S&P 500 ended off lows in a choppy afternoon session that saw the benchmark almost reverse losses of more than 1%, before selling pressure gathered pace in the final minutes of trading. The Nasdaq 100 underperformed, with semiconductors among the worst performers after Washington’s move to furth
There are multiple assistance programs available for first-time homebuyers. Here are five options to consider.
U.S-listed shares of Qiagen rose 8% while Bio-Rad fell nearly 10% after the report. Bio Rad, which manufactures and supplies products such as laboratory apparatus, instruments and diagnostics, has a market-cap of $12.85 billion. Both Qiagen and Bio-Rad did not immediately respond to Reuters' requests for comments.
Merck & Company Inc. is hiring synthetic biology firm Ginkgo Bioworks Holdings Inc. to engineer a crucial component of some of its medicines.
An already strained U.S. stock market will be further challenged in the week ahead as the government publishes a key inflation report and megabanks kick off what’s likely to be a murky earnings season.
While British households head into a winter of soaring energy costs, a tumbling currency and nearly double-digit inflation, the country's banks are in line for a handsome payday as mortgage prices spike after a decade of stagnation. Banks are finding the home loan market stacked in their favour after years of low mortgage rates, but are also aware that bigger mortgage bills could spell trouble for cash-strapped customers. Some investors and analysts are already questioning whether banks' risk models are up to the task of identifying loans that will turn a profit from those which could cost lenders dearly in the long run.
USDC's utility has taken a hit in the wake of Binance's decision to consolidate order books and Circle's decision to freeze addresses associated with Tornado Cash.
R5 Capital downgrades the stock to Hold from Buy, arguing that the slowdown in the housing sector could impact the home-improvement company.
Columbus Day arrives this year after investors navigated choppy waters last week. The marked its largest two-day gain since April 2020 on Tuesday, after a weak ISM manufacturing activity report and other economic data suggested the Federal Reserve might ease future interest-rate hikes. This week, investors can expect third-quarter earnings results, the September consumer price index reading, and other macro data to give better clues as to whether the Fed will be able to negotiate a soft landing or plunge the U.S. into a recession.
The annual IMF/World Bank meetings in Washington D.C. from Monday to Saturday will include talks on a number of emerging markets squeezed by rising inflation and borrowing costs against a backdrop of slowing global growth. The economic hit from Russia's invasion of Ukraine has added to pressures that surfaced during the COVID-19 pandemic and has led many smaller developing economies to turn to the International Monetary Fund in recent months for help. The IMF has approved programmes or financing facilities for 10 countries since the start of the Ukraine war on Feb. 24 worth a combined $77 billion, London-based Tellimer estimates.
Stocks surged 5.7% on Monday and Tuesday and then shed almost all of those gains on Wednesday, Thursday, and Friday.
The problems that both protocols suffered are reminders that neither is really decentralized, and that they are not yet true challengers to Ethereum; ether and other altcoins trade sideways.
Income investing with stocks is appealing in a crummy market. After all, why not pocket income from stocks when share-price gains are rare, right?